既往心肌梗死患者长期替格瑞洛治疗的成本效益:PEGASUS-TIMI 54试验结果
本研究基于PEGASUS-TIMI 54试验,从美国医疗系统视角评估既往1-3年内发生心肌梗死患者长期使用替格瑞洛60mg每日两次联合低剂量阿司匹林的成本效益。结果显示,替格瑞洛组终身QALY增益0.078,增量成本7435美元,ICER为94917美元/QALY,提示中等价值;在高危亚组中ICER更有利。
要点
- 替格瑞洛60mg联合低剂量阿司匹林在既往心梗患者中ICER为94917美元/QALY,提示中等成本效益。
- 高龄、多支病变、糖尿病、肾功能不全及外周动脉疾病等高危亚组ICER更有利。
- 住院成本两组相似,但替格瑞洛组总成本更高,主要因药物费用增加。
核心结论
- 对于既往心肌梗死超过1年的患者,长期替格瑞洛60mg联合低剂量阿司匹林治疗的成本效益比提示中等价值。
- 替格瑞洛在多个公认的高危亚组中提供更高的价值。
研究设计与样本
- 基于PEGASUS-TIMI 54试验的前瞻性经济学亚研究,随机分配21162例患者至阿司匹林单药、替格瑞洛60mg每日两次联合低剂量阿司匹林或替格瑞洛90mg每日两次联合低剂量阿司匹林组。
- 收集 median 33个月随访期间的医疗资源使用数据,从美国医疗系统视角评估成本,并结合终身预测评估替格瑞洛60mg每日两次方案的终身成本效益。
主要发现
- 替格瑞洛60mg组与安慰剂组住院成本相似(2262美元 vs. 2333美元;差值95%CI -303至163美元;p=0.54)。
- 纳入替格瑞洛60mg每日费用10.52美元后,替格瑞洛组总成本更高(10016美元 vs. 2333美元;95%CI 7441至7930美元;p<0.001)。
- 试验期间质量调整生命年(QALY)相似(2.28 vs. 2.27;p=0.34)。
- 终身 horizon 下,替格瑞洛组QALY增益0.078,增量成本7435美元,ICER为94917美元/QALY。
- 多个高危亚组ICER更有利:既往心梗>1次、多支病变、糖尿病、肾功能不全(ICER均在50000至70000美元/QALY之间),年龄<75岁(ICER=44779美元/QALY),外周动脉疾病(ICER=13427美元/QALY)。
关键数值与推荐
- 替格瑞洛60mg每日两次联合低剂量阿司匹林用于既往心肌梗死>1年的患者,ICER为94917美元/QALY。
- 高危亚组包括既往心梗>1次、多支病变、糖尿病、肾功能不全(ICER 50000-70000美元/QALY),年龄<75岁(ICER 44779美元/QALY),外周动脉疾病(ICER 13427美元/QALY)。
临床怎么用
- 对于既往心肌梗死超过1年的患者,长期替格瑞洛60mg联合低剂量阿司匹林具有中等成本效益,可考虑用于高危亚组以提升价值。
- 临床决策时需结合患者出血风险及经济因素,尤其在高危亚组中替格瑞洛的成本效益更优。
局限性
- 成本评估基于美国医疗系统视角,结果可能不适用于其他医疗体系。
- 终身预测依赖模型假设,可能存在不确定性。
- 试验期间QALY差异不显著,终身增益主要来自模型外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with a myocardial infarction (MI) 1 to 3 years earlier, treatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) death, MI, or stroke compared with low-dose aspirin alone, but at an increased risk of major bleeding. OBJECTIVES: The authors evaluated cost-effectiveness of ticagrelor + low-dose ASA in patients with prior MI within the prior 3 years. METHODS: The authors performed a prospective economic substudy alongside the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA. Medical resource use data were collected over a median 33-month follow-up. Costs were assessed from the U.S. health care system perspective. In-trial data relating to survival, utility, and costs were combined with lifetime projections to evaluate lifetime cost-effectiveness of the Food and Drug Administration-approved lower-dose ticagrelor regimen (60 mg twice daily). RESULTS: Hospitalization costs were similar for ticagrelor 60 mg and placebo ($2,262 vs. $2,333; 95% confidence interval for difference -$303 to $163; p = 0.54); after inclusion of a daily ticagrelor 60 mg cost of $10.52, total costs were higher for ticagrelor ($10,016 vs. $2,333; 95% CI: $7,441 to $7,930; p < 0.001). In-trial quality-adjusted life-years (QALYs) were similar (2.28 vs. 2.27; p = 0.34). Over a lifetime horizon, ticagrelor was associated with QALY gains of 0.078 and incremental costs of $7,435, yielding an incremental cost-effectiveness ratio (ICER) of $94,917/QALY gained. Several high-risk groups had more favorable ICERs, including patients with >1 prior MI, multivessel disease, diabetes, renal dysfunction (all with ICERs $50,000 to $70,000/QALY gained), patients age <75 years (ICER = $44,779/QALY gained), and patients with peripheral artery disease (ICER = $13,427/QALY gained). CONCLUSIONS: For patients with a history of MI >1 year previously, long-term treatment with ticagrelor 60 mg + low-dose ASA yields a cost-effectiveness ratio suggesting intermediate value based on current guidelines. Ticagrelor appears to provide higher value for patients in several recognized high-risk subgroups. (Prevention of Cardiovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562).
引用
- Magnuson EA, Li H, Wang K, et al. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2017. PMID: 28750695. doi:10.1016/j.jacc.2017.05.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。